PetVivo Holdings, Inc.
PETV Healthcare Medical Devices
PetVivo Holdings, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, up 0.80% from fiscal 2025. In the quarter to June 2026, revenue grew 13.5%, EPS grew 44.4% and free cash flow grew 40.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow PETV
PetVivo Holdings, Inc. (PETV) Altman Z-score
PetVivo Holdings, Inc.'s Altman Z-score for fiscal 2026 is −38.64, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −38.64 | (23.85) |
| FY2025 | −14.79 | 29.81 |
| FY2024 | −44.60 | (1.75) |
| FY2023 | −42.85 | (37.07) |
| FY2022 | −5.78 | 78.61 |
| FY2021 | −84.40 | 75.78 |
| FY2020 | −160.18 | (121.81) |
| FY2018 | −38.37 | 22.32 |
| FY2017 | −60.69 | (62.22) |
| FY2016 | 1.53 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.13 | — | 0.16 | |
| Retained earnings / total assets | (28.54) | — | −39.95 | |
| EBIT / total assets | (2.53) | — | −8.36 | |
| Market value of equity / total liabilities | 15.33 | — | 9.20 | |
| Sales / total assets | 0.32 | — | 0.32 | |
| Altman Z-score | Distress zone | −38.64 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −107.50 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IRIX IRIDEX Corporation compare | −2.0× |
| CTSO Cytosorbents Corporation compare | −9.2× |
| LFWD Lifeward Ltd. compare | −18.8× |
| HSCS HeartSciences Inc. compare | −27.9× |
| ALUR Allurion Technologies, Inc. compare | −29.6× |
| BTCY Biotricity Inc. compare | −33.3× |
| PETV PetVivo Holdings, Inc. | −38.6× |
| SINT SINTX TECHNOLOGIES, INC. compare | −45.4× |
| RBOT Vicarious Surgical Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets